Key result
Atorvastatin cuts endothelial caveolin-1 abundance up to ~75%, enhancing eNOS activity.
Why the study?
Hypercholesterolemia impairs endothelial NO-dependent vasodilation by increasing caveolin-1 abundance and stabilizing its inhibitory interaction with eNOS, but the effect of HMG-CoA reductase inhibition on this pathway is unclear.
Does atorvastatin improve nitric oxide production and eNOS activity by modulating caveolin-1 abundance in endothelial cells?
Does atorvastatin improve nitric oxide production and eNOS activity by modulating caveolin-1 abundance in endothelial cells?
Atorvastatin promotes nitric oxide production in endothelial cells by decreasing caveolin-1 expression, providing a biochemical mechanism for its benefits in correcting endothelial dysfunction associated with hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Atorvastatin boosts endothelial NO via caveolin-1 reduction in cell studies; leaves open any clinical relevance for endothelial dysfunction.
Féron et al. (2001) studied Hypercholesterolemia. Atorvastatin vs. Control (absence of atorvastatin) was evaluated on Caveolin-1 abundance and eNOS activity. Atorvastatin reduced caveolin-1 abundance by up to 75% and increased basal and agonist-stimulated eNOS activity by 45% and 107%, respectively, in endothelial cells.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: